IIBR's article: "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge" is at Nature communication Top 50 read articles of 2020
This is our vaccine's story from research to production
"Bri", alludes to the Hebrew word for health, "briut,", "iL" alludes to Israel, and "life" speaks to the importance of the vaccine. The name of the institute, IIBR is also hidden there with pride.
An important milestone was completed.
Selected excerpts from IIBR’s Director General, Prof. Shmuel C. Shapira’s session to the Science and Technology Committee at The Knesset
IIBR will continue to characterize these antibodies and others and a biological manufacture would be sought to mass produce it for clinical use.
A joint ongoing study led by IIBR researchers and physicians from Laniado and Assuta Ashdod hospitals tested the viability of corona virus in patient‘s environment surfaces. The study reveals low probability of being infected due to surface contact.
IIBR Director General, Professor Shmuel Shapira, informed Prime Minister Benjamin Netanyahu of "significant progress" in designing a vaccine prototype and that the institute "is now preparing a model for commencing an animal trial".
The Israel institute for biological research is assigned by the Israeli Prime mister, Mr. Benjamin Netanyahu, to produce a vaccine and antibody for the Novel Coronavirus.